Company: MIRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024077
Chunk: 35

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 2
Chunk 35
---
, or claims are pending against us or involve us that, in the opinion of our management, could
reasonably be expected to have a material adverse effect on our business and financial condition.

We
anticipate that we will expend significant financial and managerial resources in the defense of our intellectual property rights in the
future if we believe that our rights have been violated. We also anticipate that we will expend significant financial and managerial
resources to defend against claims that our products and services infringe upon the intellectual property rights of third parties.

Item
1A. Risk Factors.

As
a smaller reporting company, information under this “Item 1A. Risk Factors” is not required to be presented.

Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item
3. Defaults upon Senior Securities.

None.

Item
4. Mine Safety Disclosures.

Not
applicable.

Item
5. Other Information.

Not
applicable.

20

Item
6. Exhibits.

    Number
     
    Description

    31.1*
     
    Certification
    of Chief Executive Officer Pursuant to Sarbanes-Oxley Section 302

    31.2*
     
    Certification
    of Interim Chief Financial Officer Pursuant to Sarbanes-Oxley Section 302

    32.1**
     
    Certification
    Pursuant To 18 U.S.C. Section 1350 (*)

    32.2**
     
    Certification
    Pursuant To 18 U.S.C. Section 1350 (*)

    101.ins*
     
    Inline
    XBRL Instance Document

    101.sch*
     
    Inline
    XBRL Taxonomy Extension Schema Document

    101.cal*
     
    Inline
    XBRL Taxonomy Calculation Linkbase Document

    101.def*
     
    Inline
    XBRL Taxonomy Definition Linkbase Document

    101.lab*
     
    Inline
    XBRL Taxonomy Label Linkbase Document

    101.pre*
     
    Inline
    XBRL Taxonomy Presentation Linkbase Document

    104*
     
    The
    cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, formatted in Inline XBRL.

    *
     
    Filed
    herewith.

    **
     
    Furnished
    herewith.

21

SIGNATURES